Enzychem Lifesciences, a global biopharmaceutical company focusing on innovative medical countermeasure development, will present at Biotech Showcase™ 2019 investor conference, to be held January 7–9 in San Francisco.
EC-18, the lead compound of Enzychem Lifesciences, is an immune modulator driven from deer antler that has the potential to be used for a variety of indications. At present, three clinical trials for different indications are being conducted; Chemotherapy Induced Neutropenia (CIN), Chemoradiation Induced Oral Mucositis (CRIOM), and Acute Radiation Syndrome (ARS).
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and executives in one place during the course of one of the industry’s largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Acute Radiation Syndrome
Caused by a critical exposure to radiation, acute radiation syndrome includes neutropenia, nervous system damage, and pneumonia with high fatality rate.
The US Food and Drug Administration (FDA) granted Orphan Drug Designation to EC-18 for the treatment of Acute Radiation Syndrome (ARS) in Jan 2018. The Orphan Drug Designation program provides incentives to companies that are developing therapies for rare diseases which affect fewer than 200,000 people in the US. The designation qualified the company to receive a seven-year term of market exclusivity upon FDA approval of the orphan drug and tax credits for clinical research costs.
Enzychem Lifesciences is headquartered in Seoul, Korea. In order to facilitate the clinical trial process, Enzychem launched a US operation in New Jersey.
— from our partner —